相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
T. Susanna Meijer et al.
ANNALS OF SURGICAL ONCOLOGY (2021)
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial)
Mario Campone et al.
EUROPEAN JOURNAL OF CANCER (2021)
Ortho- and Ectopic Zebrafish Xeno-Engraftment of Ocular Melanoma to Recapitulate Primary Tumor and Experimental Metastasis Development
Arwin Groenewoud et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2021)
Inhibition of DNA-PKcs activity re-sensitizes uveal melanoma cells to radio- and chemotherapy
Bingjie Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann et al.
MOLECULAR CANCER THERAPEUTICS (2020)
A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma
Jane Mattei et al.
MELANOMA RESEARCH (2020)
Increased Non-Homologous End Joining Makes DNA-PK a Promising Target for Therapeutic Intervention in Uveal Melanoma
Rachel E. Doherty et al.
CANCERS (2019)
Differential Expression of DNA Repair Genes in Prognostically-Favorable versus Unfavorable Uveal Melanoma
Mehmet Dogrusoz et al.
CANCERS (2019)
First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy
Pamela Munster et al.
CANCER MANAGEMENT AND RESEARCH (2019)
A Phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma
Ellen Kapiteijn et al.
CANCER RESEARCH (2019)
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma (vol 32, pg 204, 2017)
A. Gordon Robertson et al.
CANCER CELL (2018)
A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma
Cun Wang et al.
CELL RESEARCH (2018)
Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence
Lingaku Lee et al.
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer The BOLERO-6 Randomized Clinical Trial
Guy Jerusalem et al.
JAMA ONCOLOGY (2018)
How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma
Theresa Steeb et al.
EUROPEAN JOURNAL OF CANCER (2018)
c15-160: Enzalutamide (ENZA) plus CC-115 in men with metastatic castration-resistant prostate cancer (mCRPC): A phase 1b Prostate Cancer Clinical Trials Consortium study.
Dana E. Rathkopf et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma
Hanyin Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2017)
CC-115, a dual inhibitor of mTOR kinase and DNA-PK, blocks DNA damage repair pathways and selectively inhibits ATM-deficient cell growth in vitro
Toshiya Tsuji et al.
ONCOTARGET (2017)
RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma
Xu Chen et al.
CANCER CELL (2017)
Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4
Peter Johansson et al.
ONCOTARGET (2016)
A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma
Alexander N. Shoushtari et al.
MELANOMA RESEARCH (2016)
Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma
Amanda R. Moore et al.
NATURE GENETICS (2016)
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
Nabil Amirouchene-Angelozzi et al.
ONCOTARGET (2016)
Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
Guillaume Carita et al.
ONCOTARGET (2016)
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Eleonora M. de Leede et al.
JOVE-JOURNAL OF VISUALIZED EXPERIMENTS (2016)
Differential Phosphorylation of DNA-PKcs Regulates the Interplay between End-Processing and End-Ligation during Nonhomologous End-Joining
Wenxia Jiang et al.
MOLECULAR CELL (2015)
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer
Johanna C. Bendell et al.
INVESTIGATIONAL NEW DRUGS (2015)
Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing
H. Kalirai et al.
BRITISH JOURNAL OF CANCER (2014)
Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
Fa-Xing Yu et al.
CANCER CELL (2014)
Establishment of novel cell lines recapitulating the genetic landscape of uveal melanoma and preclinical validation of mTOR as a therapeutic target
Nabil Amirouchene-Angelozzi et al.
MOLECULAR ONCOLOGY (2014)
Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
Makoto Yoshida et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity
Adrienne L. Watson et al.
ONCOTARGET (2014)
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Wei Li et al.
GENOME BIOLOGY (2014)
Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
Grazia Ambrosini et al.
MOLECULAR CANCER THERAPEUTICS (2013)
GNAQ and BRAF mutations show differential activation of the mTOR pathway in human transformed cells
Helena Populo et al.
PEERJ (2013)
Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways
Xinqi Wu et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial
Gerald S. Falchook et al.
LANCET ONCOLOGY (2012)
Fiji: an open-source platform for biological-image analysis
Johannes Schindelin et al.
NATURE METHODS (2012)
Genetic and molecular characterization of uveal melanoma cell lines
K. G. Griewank et al.
PIGMENT CELL & MELANOMA RESEARCH (2012)
Combination mTOR plus IGF-IR inhibition: Phase I trial of everolimus and CP-751871 in patients (pts) with advanced sarcomas and other solid tumors
R. H. Quek et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
Helena Populoa et al.
MELANOMA RESEARCH (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The PI3K/Akt and mTOR/P70S6K Signaling Pathways in Human Uveal Melanoma Cells: Interaction with B-Raf/ERK
Narjes Babchia et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)
Juan M. Garcia-Martinez et al.
BIOCHEMICAL JOURNAL (2009)
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer
Arkaitz Carracedo et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Incidence of uveal melanoma in Europe
Gianni Virgili et al.
OPHTHALMOLOGY (2007)
Vascular endothelial growth factor A in eyes with uveal melanoma
Guy S. O. Missotten et al.
ARCHIVES OF OPHTHALMOLOGY (2006)
Clinical and cytogenetic analyses in uveal melanoma
Emine Kilic et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2006)
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441
Yan Zhao et al.
CANCER RESEARCH (2006)
High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma
MH Abdel-Rahman et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
c-Kit-dependent growth of uveal melanoma cells:: A potential therapeutic target?
C All-Ericsson et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2004)
Screening for metastasis from choroidal melanoma: The Collaborative Ocular Melanoma Study Group report 23
M Diener-West et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Very long-term prognosis of patients with malignant uveal melanoma
E Kujala et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2003)
In vivo imaging of embryonic vascular development using transgenic zebrafish
ND Lawson et al.
DEVELOPMENTAL BIOLOGY (2002)
DNA-PK inhibitor wortmannin enhances DNA damage induced by bleomycin in V79 Chinese hamster cells
NG Oliveira et al.
TERATOGENESIS CARCINOGENESIS AND MUTAGENESIS (2002)
Activation of NF-κB by bradykinin through a Gαq-and Gβγ-dependent pathway that involves phosphoinositide 3-kinase and Akt
P Xie et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
分享论文
